Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - estradiol 2mg (releases 25 µg/24 hours);   - transdermal patch - 25 mcg/24h - active: estradiol 2mg (releases 25 µg/24 hours)   excipient: ethanol hyprolose

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 7.84mg equivalent to estradiol 7.59 mg (100 µg/24h) - transdermal patch - 100 mcg/24h - active: estradiol hemihydrate 7.84mg equivalent to estradiol 7.59 mg (100 µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 3.92mg equivalent to estradiol 3.79 mg (50 µg/24h) - transdermal patch - 50 mcg/24h - active: estradiol hemihydrate 3.92mg equivalent to estradiol 3.79 mg (50 µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 5.88mg equivalent to estradiol 5.69 mg (75µg/24h) - transdermal patch - 75 mcg/24h - active: estradiol hemihydrate 5.88mg equivalent to estradiol 5.69 mg (75µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

hospira nz ltd - estradiol 2mg equivalent to 25 µg/24h - transdermal patch - 2 mg(25mcg / 24h) - active: estradiol 2mg equivalent to 25 µg/24h excipient: acrylic copolymer, durotak 326-1753 acrylic copolymer, durotak 387-2287

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - estradiol 4.33mg equivalent to 50 µg/24h oestradiol; estradiol hemihydrate 0.62mg equivalent to oestradiol 50 µg/24 hours;  ; norethisterone acetate 2.7mg equivalent to norethisterone acetate 140 µg/24 hours;   - transdermal patch - 50 + 50/140 - active: estradiol 4.33mg equivalent to 50 µg/24h oestradiol excipient: 1,3-butylene glycol acrylic adhesive bentonite dipropylene glycol ethylenevinylacetate copolymer lecithin liquid paraffin oleic acid polyisobutylene synthetic adhesive active: estradiol hemihydrate 0.62mg equivalent to oestradiol 50 µg/24 hours   norethisterone acetate 2.7mg equivalent to norethisterone acetate 140 µg/24 hours   excipient: acrylic adhesive dipropylene glycol oleic acid povidone silicone adhesive

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - estradiol 0.312 mg/cm² equivalent to 25 µg/24h;   - transdermal patch - 25 mcg/24h - active: estradiol 0.312 mg/cm² equivalent to 25 µg/24h   excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 2.04mg equivalent to estradiol 1.97 mg (25 µg/24h) - transdermal patch - 25 mcg/24h - active: estradiol hemihydrate 2.04mg equivalent to estradiol 1.97 mg (25 µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

physicians total care, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e), norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - estradiol 1 mg - estradiol/norethindrone acetate tablets 1.0 mg/0.5 mg and 0.5 mg/0.1 mg are indicated in women who have a uterus for the: - treatment of moderate to severe vasomotor symptoms associated with menopause. - prevention of postmenopausal osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered. the mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin d intake, and when indicated, pharmacologic therapy. postmenopausal women require an average of 1500 mg/day of elemental calcium. therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. vitamin d supplementation of 400-800 iu/day may also be required to ensure adequate daily intake in postmenopausal women. estradiol/norethindrone acetate tablets 1.0 mg/0.5 mg is also in

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e), norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - estradiol 1 mg - estradiol/norethindrone acetate tablets are indicated for:   limitation of use when prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products. limitation of use when prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. consider estrogen therapy only for women at significant risk of osteoporosis. estradiol/norethindrone acetate tablets are contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding [see warnings and precautions (5.2)] - breast cancer or history of breast cancer [see warnings and precautions (5.2)] - estrogen-dependent neoplasia [see warnings and precautions (5.2)] - active dvt, pe, or history of these conditions [see warnings and precautions (5.1)] - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions [see warnings and precauti